A 52-year-old man was referred for incidental detection of chronic hepatitis C, genotype 1. Viral load was 13.500.000 IU/mL. A liver biopsy showed 4/6 fibrosis. Treatment was initiated with subcutaneous pegylated IFN (Peg-IFN) α-2a injections on a weekly basis and oral ribavirin 800 mg daily. At 2 weeks after starting the therapy, the patient noticed brown pigmetation on his face, which gradually increased until the end of the course of therapy (48 weeks) ( Figure 1 ). There were no other areas of involvement. A biopsy was taken from the face skin and increased numbers of melanocytes were observed in the basal layer of the epithelium (Figure 2 ). Informed consent was taken from the patient about this publication.
Generally, there are only heterogenous, mild, cutaneous side effects resulting from IFN and ribavirin treatment, although on very rare occasions, severe reactions can occur. While injection-site reaction is the most frequently seen cutaneous side-effect of IFN, transient alopecia, vasculitis, cutaneous necrosis, lichen planus and psoriasis have also been reported (2) . The combination of oral ribavirin with Peg-IFN (either alfa-2a or-2b) has been associated with alopecia, pruritus, dermatitis, dry skin, increased sweating, and generalized morbiliform rash. Hyperpigmentation of the tongue, face or body skin has been mainly described in dark-skinned patients. Although it is usually asymptomatic, there may be a burning sensation and onset generally develops in the first weeks and disappears after the end of the therapy. The mechanism is not fully known, but it is thought Turk J Gastroenterol 2015; 26: 189-90 Letter to the Editor Face skin hyperpigmentation during pegylated interferon and ribavirin therapy
